Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE: MRI-Guided Boost SCPRT vs Long-Course CRT in Rectal Cancer
NCT03714490Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2018
- Primary completion
- Sep 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, capecitabine in rectal cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Oct 2018; status: recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03714490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714490.